The purpose of this study is to evaluate participant treatment experience with Povetacicept injection administered via autoinjector relative to Sibeprenlimab injection administered via prefilled syringe (PFS), and to assess the safety and tolerability of Povetacicept in participants with Immunoglobulin A nephropathy (IgAN).
No linked publications found in PubMed
Key Inclusion Criteria: * Receiving commercial sibeprenlimab 400 mg subcutaneous via PFS for up to (but not exceeding) a maximum of 4 doses of which at least 1 dose is self-injected prior to signing informed consent form * Willing and able to comply with scheduled visits, treatment plan including transitioning to povetacicept * Biopsy-confirmed primary IgAN * 24-hr urine protein/creatinine ratio (UPCR) greater than \>0.5 gram (g)/g * Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 30 millilitres per minute (mL/min)/1.73 square meter (m\^2) * Able to understand and complete the domains of the Self-Injection Administration Questionnaire (SIAQ) Key Exclusion Criteria: * Use of immunosuppressive or immunomodulatory therapies (except for sibeprenlimab) * Rapidly progressive glomerulonephritis with eGFR reduction \>50% within 12 weeks of the start of screening Other protocol defined Inclusion/Exclusion criteria may apply.